As per Future Market Insights (FMI), the demand in the PARP Inhibitors Market is expected to surpass US$ 8.43 Bn, growing at an impressive CAGR of 11.2% during the forecast period 2022-2026. Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year.
The incidence of breast cancer is much higher in these countries, and with superior efficacy of PARP inhibitors as compared to other available cancer treatment options, the PARP inhibitors market is expected to gain significant revenue over the forecast period.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3197
“The unique ability of PARP inhibitors to improve progression-free survival in ovarian and breast cancer patients is expected to generate extensive traction for the market, thereby propelling the growth of the global PARP inhibitors market over the forecast period.”
Key Takeaways of PARP Inhibitors Market Study
- Olaparib, with various expanded approvals for the treatment of ovarian cancer, breast cancer, and pancreatic cancer, and rapid increase in potential patient pool, contributed to the dominance of the segment by drug in 2021, and will continue to do so during the forecast period.
- PARP inhibitors are regarded as a new standard of care for ovarian cancer after first-line platinum chemotherapy. Adoption of PARP inhibitors for ovarian cancer treatment has surged, and the trend is expected to continue during the forecast period, owing to the ability of PARP inhibitors to induce ovarian cancer patients into remission for longer periods of time as compared to any other marketed therapy.
- With a strong pipeline, significant number of PARP inhibitors are expected to go for approval through the new drug application (NDA) process and for expanded approval to treat various types of cancers.
Strategic Acquisitions & Collaborations by Key Players to Widen Regional Presence
All marketed PARP inhibitors are under patent, and with no generic launch in sight till 2027, the market is expected to remain consolidated till the second half of this decade. Key players in the PARP inhibitors market are undergoing major collaborative efforts, mergers, and acquisitions in order to expand their regional product offerings.
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-3197
For example, in January 2022, GlaxoSmithKline plc acquired TESARO Inc., an oncology-focused biopharmaceutical company with a marketed PARP inhibitor named Zejula (Niraparib).
More Valuable Insights on PARP Inhibitors Market
Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2015 to 2026. The global PARP inhibitors market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The study provide compelling insights on PARP inhibitors market on basis of drug (Olaparib, Niraparib, Rucaparib, and Talazoparib), indication (ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer), and distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), across seven major regions.
PARP Inhibitors Market by Category By Drug Type:
- Olaparib
- Niraparib
- Rucaparib
- Talazoparib
By Indication:
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
For more Report Customization, connect with us at@ https://www.futuremarketinsights.com/customization-available/rep-gb-3197
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 05-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs